Stock Rating: Time To “Buy” SciClone Pharma (NASDAQ:SCLN), Maxim Group Says. Stock Worth $14

November 29, 2016 - By Linda Rogers

Stock Rating: Time To

Why Maxim Group Gives SciClone Pharma (NASDAQ:SCLN) $14 Price Target

In a an analyst report released today, Maxim Group analysts started SciClone Pharma (NASDAQ:SCLN) coverage with a “Buy” rating, and a $14 target price.

The stock increased 0.49% or $0.05 during the last trading session, hitting $10.25. SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has declined 22.11% since April 26, 2016 and is downtrending. It has underperformed by 27.37% the S&P500.

Analysts await SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) to report earnings on March, 9.

Insitutional Activity: The institutional sentiment increased to 1.34 in Q2 2016. Its up 0.16, from 1.18 in 2016Q1. The ratio improved, as 26 funds sold all SciClone Pharmaceuticals, Inc. shares owned while 41 reduced positions. 32 funds bought stakes while 47 increased positions. They now own 38.22 million shares or 3.91% more from 36.79 million shares in 2016Q1.

The California-based Eqis Mngmt has invested 0.02% in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Blackrock Inc has 0% invested in the company for 6,920 shares. Goldman Sachs Inc holds 0% or 296,789 shares in its portfolio. Shinko Asset Mgmt Limited, a Japan-based fund reported 324,651 shares. Schwab Charles Inc has 477,634 shares for 0.01% of their US portfolio. Acadian Asset Ltd Liability Company has invested 0.13% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Moreover, Dimensional Fund Ltd Partnership has 0.02% invested in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 2.61 million shares. Dekabank Deutsche Girozentrale owns 27,600 shares or 0% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Renaissance Technologies Lc has invested 0.03% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Blackrock Institutional Tru Na last reported 1.60 million shares in the company. The New Jersey-based Systematic Management Ltd Partnership has invested 0.02% in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Moreover, Texas Permanent School Fund has 0.01% invested in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 38,162 shares. Denver Investment Limited Liability Company has 0.01% invested in the company for 10,678 shares. Royal Comml Bank Of Canada accumulated 0% or 1,700 shares.

Insider Transactions: Since August 12, 2016, the stock had 0 insider purchases, and 14 sales for $11.13 million net activity. Xie Lan sold $340,221 worth of stock. 40,500 shares were sold by Zhao Hong, worth $421,605 on Friday, August 12. Cheung Wilson Wai-Shun also sold $1.50M worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) on Tuesday, October 25. The insider Blobel Friedhelm sold $371,892. King Robert had sold 48,667 shares worth $506,623 on Friday, August 12. Hawkins Richard J also sold $1.24M worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) on Friday, August 12. The insider CHANG NANCY T sold $257,896.

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $525.88 million. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. It has a 13.69 P/E ratio. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong.

According to Zacks Investment Research, “Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world’s most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.”

SCLN Company Profile

SciClone Pharmaceuticals, Inc. (SciClone), incorporated on June 26, 2003, is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets approximately seven partnered and in-licensed products in China. The Firm sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

More recent SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on October 28, 2009. Also Prnewswire.com published the news titled: “SciClone Pharmaceuticals To Report Third Quarter 2016 Financial Results On …” on October 25, 2016. Quotes.Wsj.com‘s news article titled: “DOW JONES, A NEWS CORP COMPANY” with publication date: February 12, 2011 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>